By Carlo Martuscelli

Bayer AG (BAYN.XE) said Thursday that it is investing up to $100 million to research new treatments for cardiovascular and gynecological diseases with U.S. biotech Dewpoint Therapeutics.

The two companies signed an option, research and license agreement, Bayer said. Under the terms of the deal it will use Dewpoint's biomolecular condensates platform to drive research into the disease areas.

Germany's Bayer also said that it will have the option to exclusively license new therapy candidates developed from the research activities.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

November 14, 2019 08:47 ET (13:47 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Bayer